Attached files

file filename
10-K - 10-K - Precision Therapeutics Inc.v214104_10k.htm
EX-3.2 - Precision Therapeutics Inc.v214104_ex3-2.htm
EX-3.1 - Precision Therapeutics Inc.v214104_ex3-1.htm
EX-31.2 - EX-31.2 - Precision Therapeutics Inc.v214104_ex31-2.htm
EX-23.1 - EX-23.1 - Precision Therapeutics Inc.v214104_ex23-1.htm
EX-31.1 - EX-31.1 - Precision Therapeutics Inc.v214104_ex31-1.htm
EX-14.1 - Precision Therapeutics Inc.v214104_ex14-1.htm
 
Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of BioDrain Medical, Inc. (the "Company") for the year ended December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Kevin R. Davidson., Chief Executive Officer and Chief Financial Officer, of the Company, certify, pursuant to § 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. § 1350, that to my knowledge:

(1)  The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)  The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 31, 2011
 
/s/ Kevin R. Davidson
Kevin R. Davidson
Chief Executive Officer and Chief Financial Officer
(Principal Executive Officer and Principal Financial Officer)